However, the recent EMPACT-MI and DAPA-MI trials, which explored the use of SGLT2 inhibitors following an acute MI, failed to demonstrate a reduction in first hospitalization for heart failure (HF) or death from any cause (75) nor in the composite of CV death or hospitalization for HF (76) compared with placebo. The gene discussed is SLC5A2; the disease is hydrops fetalis.